Extended Data Fig. 4: VARS depletion resensitizes melanoma tumors to MAPK-therapy.
From: Valine aminoacyl-tRNA synthetase promotes therapy resistance in melanoma
a, A375 RES control or VARS-depleted melanoma cells (shVARS-2) were xenografted in mice and treated or not with Vemurafenib (25 mg/kg). Tumor weight was assessed and plotted (n = 12 for each group). Mean ± SEM is represented. Two-way ANOVA was performed. Tukey’s multiple comparison tests are indicated in the figures.
